Results of TRODELVY® real-world data

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Skin Cancer

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Eur J Cancer

Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C

doi: 10.1016/j.ejca.2024.115160

CHICAGO 2025

Genitourinary Cancer

PRECISION: Real-world outcomes following guideline-recommended therapies after ¹⁷⁷Lu-PSMA-617 in mCRPC

CHICAGO 2025

Genitourinary Cancer

Earlier initiation of ¹⁷⁷Lu-PSMA-617 is associated with improved clinical outcomes in patients with mCRPC in a real-world setting

ASH 2024

Lymphoma

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Multiple Myeloma (MM)

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis

Leuk Lymphoma

Varma G, Fogel L, Gordon B, Saldarriaga MM, Ahn J, Aleman A, Caro J, Rosenberg MC, Monge J, Parmar H, Kaminetzky D, Moskovits T, Siegel DS, Morgan GJ, Niesvizky R, Davies FE, Biran N

doi: 10.1080/10428194.2024.2446617

Leukemia

Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting

Br J Haematol

Suttorp M, Sembill S, Lensker P, Hildebrand V, Schirmer E, Karow A, Krumbholz M, Rauh M, Metzler M

doi: 10.1111/bjh.20047

Lung, Respiratory and Thoracic Cancer

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study

Lung Cancer

Shah R, Buchmeier EL, Kopp HG, Christoph DC, Griesinger F, Reck M, Hoffknecht P, Kuon J, Frost N, Grohé C, Faehling M, Luan J, Roeper J, Chesi P, Blasi M, Kimmich M, Olchers T, Bischoff H, Klotz LV, Chung I, Christopoulos P, Thomas M

doi: 10.1016/j.lungcan.2025.108702

Oncology · Hematology

Results of TRODELVY^® real-world data

Related content

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

PRECISION: Real-world outcomes following guideline-recommended therapies after 177Lu-PSMA-617 in mCRPC

Earlier initiation of 177Lu-PSMA-617 is associated with improved clinical outcomes in patients with mCRPC in a real-world setting

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis

Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

PRECISION: Real-world outcomes following guideline-recommended therapies after ¹⁷⁷Lu-PSMA-617 in mCRPC

Earlier initiation of ¹⁷⁷Lu-PSMA-617 is associated with improved clinical outcomes in patients with mCRPC in a real-world setting